Clinical Trial Update: Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) [NA]

View source ↗

Summary

Clinical trial update evaluating long-term dosing safety of romiplostim (AMG 531) in thrombocytopenic subjects with myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• AMG 531 (AMG531)
• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Hematology, MDS | NA | Status: COMPLETED | Results posted: 2013-07-15